Atcor profits from hypertension

About the author:

Author name:

By Scott Power

Job title:

Senior Analyst

Date posted:

16 September 2013, 10:08 AM

Sectors Covered:

Healthcare, Life Sciences

We caught up with Peter Manley (CFO) from Atcor Medical Holdings Ltd (ACG - current share price A$0.165) on Friday (by phone).

Atcor has had a big run and rightly so, after posting a solid profit result of A$2.7m for FY13. ACG technology enables the measurement of central blood pressure non-invasively, and is key for the early detection of hypertension. The lead product SphygmoCor is approved in the US and other parts of the world and recently gained approval in Mexico.

I expect the stock is going higher.

If you are interested in Atcor Medical Holdings Ltd (PBT), please contact your nearest Morgans office.

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.